Skip to main content
NCBI home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1991 Sep;35(9):1917–1918. doi: 10.1128/aac.35.9.1917

In vitro susceptibilities of Campylobacter jejuni and Campylobacter coli to azithromycin and erythromycin.

D E Taylor 1, N Chang 1
PMCID: PMC245292  PMID: 1659309

Abstract

MICs of azithromycin and erythromycin for 20 Campylobacter coli and 20 Campylobacter jejuni strains were determined. The results demonstrated that, for Campylobacter species, all high-level erythromycin-resistant strains were also resistant to azithromycin and that azithromycin did not exhibit increased potency in comparison with that of erythromycin.

Full text

PDF
1917

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bright G. M., Nagel A. A., Bordner J., Desai K. A., Dibrino J. N., Nowakowska J., Vincent L., Watrous R. M., Sciavolino F. C., English A. R. Synthesis, in vitro and in vivo activity of novel 9-deoxo-9a-AZA-9a-homoerythromycin A derivatives; a new class of macrolide antibiotics, the azalides. J Antibiot (Tokyo) 1988 Aug;41(8):1029–1047. doi: 10.7164/antibiotics.41.1029. [DOI] [PubMed] [Google Scholar]
  2. Burridge R., Warren C., Phillips I. Macrolide, lincosamide and streptogramin resistance in Campylobacter jejuni/coli. J Antimicrob Chemother. 1986 Mar;17(3):315–321. doi: 10.1093/jac/17.3.315. [DOI] [PubMed] [Google Scholar]
  3. Gladue R. P., Bright G. M., Isaacson R. E., Newborg M. F. In vitro and in vivo uptake of azithromycin (CP-62,993) by phagocytic cells: possible mechanism of delivery and release at sites of infection. Antimicrob Agents Chemother. 1989 Mar;33(3):277–282. doi: 10.1128/aac.33.3.277. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Hardy D. J., Hensey D. M., Beyer J. M., Vojtko C., McDonald E. J., Fernandes P. B. Comparative in vitro activities of new 14-, 15-, and 16-membered macrolides. Antimicrob Agents Chemother. 1988 Nov;32(11):1710–1719. doi: 10.1128/aac.32.11.1710. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Karmali M. A., De Grandis S., Fleming P. C. Antimicrobial susceptibility of Campylobacter jejuni with special reference to resistance patterns of Canadian isolates. Antimicrob Agents Chemother. 1981 Apr;19(4):593–597. doi: 10.1128/aac.19.4.593. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Kitzis M. D., Goldstein F. W., Miégi M., Acar J. F. In-vitro activity of azithromycin against various Gram-negative bacilli and anaerobic bacteria. J Antimicrob Chemother. 1990 Jan;25 (Suppl A):15–18. doi: 10.1093/jac/25.suppl_a.15. [DOI] [PubMed] [Google Scholar]
  7. Retsema J., Girard A., Schelkly W., Manousos M., Anderson M., Bright G., Borovoy R., Brennan L., Mason R. Spectrum and mode of action of azithromycin (CP-62,993), a new 15-membered-ring macrolide with improved potency against gram-negative organisms. Antimicrob Agents Chemother. 1987 Dec;31(12):1939–1947. doi: 10.1128/aac.31.12.1939. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Vanhoof R., Vanderlinden M. P., Dierickx R., Lauwers S., Yourassowsky E., Butzler J. P. Susceptibility of Campylobacter fetus subsp. jejuni to twenty-nine antimicrobial agents. Antimicrob Agents Chemother. 1978 Oct;14(4):553–556. doi: 10.1128/aac.14.4.553. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Walder M., Forsgren A. Erythromycin-resistant Campylobacters. Lancet. 1978 Dec 2;2(8101):1201–1201. doi: 10.1016/s0140-6736(78)92182-7. [DOI] [PubMed] [Google Scholar]
  10. Wang W. L., Reller L. B., Blaser M. J. Comparison of antimicrobial susceptibility patterns of Campylobacter jejuni and Campylobacter coli. Antimicrob Agents Chemother. 1984 Sep;26(3):351–353. doi: 10.1128/aac.26.3.351. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES